Feasibility study of PET Imaging with 64Cu-DOTA-trastuzumab in HER2 positive breast cancer
Not Applicable
Recruiting
- Conditions
- 1. Patients with invasive ductal carcinoma of breast. 2. HER2 positive (IHC 3+>or FISH positive) breast cancer 3. Currently taking or about to commence treatment with trastuzumab or trastumab based chemotherapy 4. Age: >20 years, <75 years 5. ECOG Performance Score 0 or 1. 6. Good main organ function 7. Capability to be received PET scan. 8. Signed informed consent
- Registration Number
- JPRN-UMIN000004170
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
8. 1.active concomitant malignancy 2.congestive heart failure (CHF)3.uncontrolled angina pectoris, arrhythmia 4.symptomatic infectious disease 5.severe bleeding 6.pulmonary fibrosis 7.obstructive bowel disease or severe diarrhea 8.symptomatic peripheral or cardiac effusion 9.symptomatic brain metastasis.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To find recommend dose and schedule of PET scan for molecular imaging by 64Cu-DOTA-trastuzumab.
- Secondary Outcome Measures
Name Time Method Second objective: To descover the novel molecular imaging to detect HER2 positive tumor inside the body without needle biopsy.